Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 19
HOS-086296 · Präparat HOS-083284
HCV Direct Acting Antiviral
Glecaprevir/pibrentasvir Serum concentrations may be increased due to P-glycoprotein, BCRP and OATP1B
inhibition by ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pibrentasvir (HOS-086298) glecaprevir (HOS-086297)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 2de0e836d909020f96c6ca2537544664b2cd4ed5c3bac897ca9045f497c52806 · Zeichen 41559–41762 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 19
HOS-086299 · Präparat HOS-083284
Concomitant administration of glecaprevir/pibrentasvir and ritonavir is not
recommended due to an increased risk of ALT elevations associated with increased
glecaprevir exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pibrentasvir (HOS-086298) glecaprevir (HOS-086297)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 52abfe7fea4e8072946dfa3741ce25cdebe84c8f2eb33d58b7e975f4115d1e33 · Zeichen 41801–42053 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-086469 · Präparat HOS-083284
HCV Direct Acting Antiviral
Glecaprevir/pibrentasvir Serum concentrations may be increased due to P-glycoprotein, BCRP and OATP1B
inhibition by ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pibrentasvir (HOS-086298) glecaprevir (HOS-086297)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 24b34b4049a55461ae537954f36623a8556dd23e7a6c9297861edb9df7e9b0e7 · Zeichen 43455–43666 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-086470 · Präparat HOS-083284
Concomitant administration of glecaprevir/pibrentasvir and ritonavir is not recommended
due to an increased risk of ALT elevations associated with increased glecaprevir
exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pibrentasvir (HOS-086298) glecaprevir (HOS-086297)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 35aa625f23df910492693757feddc99e5d89b621c9df450317946ec677ba137a · Zeichen 43709–43969 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 23–24
HOS-108925 · Präparat HOS-093083
23
Glecaprevir/pibrentasvir Serum concentrations may be Concomitant administration of
increased due to P-glycoprotein, glecaprevir/pibrentasvir and
BCRP and OATP1B inhibition by Kaletra is not recommended due
lopinavir/ritonavir. to an increased risk of ALT
elevations associated with
increased glecaprevir exposure.
Sofosbuvir/velpatasvir/ Serum concentrations of It is not recommended to
voxilaprevir sofosbuvir, velpatasvir and coadminister Kaletra and
voxilaprevir may be increased due sofosbuvir/velpatasvir/
to P-glycoprotein, BCRP and voxilaprevir.
OATP1B1/3 inhibition by
lopinavir/ritonavir. However,
only the increase in voxilaprevir
exposure is considered clinically
relevant.
HCV protease inhibitors
Simeprevir 200 mg daily Simeprevir: It is not recommended to
(ritonavir 100 mg BID) AUC: ↑ 7.2-fold co-administer Kaletra and
Cmax: ↑ 4.7-fold simeprevir.
Cmin: ↑ 14.4-fold
Herbal products
St John’s wort (Hypericum Lopinavir: Herbal preparations containing St
perforatum) Concentrations may be reduced John’s wort must not be combined
due to induction of CYP3A by the with lopinavir and ritonavir. If a
herbal preparation St John’s wort. patient is already taking St John’s
wort, stop St John’s wort and if
possible check viral levels.
Lopinavir and ritonavir levels may
increase on stopping
St John’s wort. The dose of
Kaletra may need adjusting. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s wort (see
section 4.3). Therefore, Kaletra
can be started safely 2 weeks after
cessation of St John's wort.
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels
due to CYP3A inhibition by of these products have been
lopinavir/ritonavir. stabilised.
Lipid lowering agents
Lovastatin and Simvastatin Lovastatin, Simvastatin: Since increased concentrations of
Markedly increased plasma HMG-CoA reductase inhibitors
concentrations due to CYP3A may cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination
of these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) protease (HOS-085623) lovastatin (HOS-086157) pibrentasvir (HOS-086298) lomitapide (HOS-086160) simvastatin (HOS-086158) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) tacrolimus (HOS-085202) velpatasvir (HOS-108929) simeprevir (HOS-086302) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage d661859df9e7416124e84f058321f8363c31c96c6c3cbfadb04946272feb4ff7 · Zeichen 52766–57555 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-109021 · Präparat HOS-093083
Lopinavir: ↔
Glecaprevir/pibrentasvir Serum concentrations may be Concomitant administration of
increased due to P-glycoprotein, glecaprevir/pibrentasvir and Kaletra
BCRP and OATP1B inhibition by is not recommended due to an
lopinavir/ritonavir. increased risk of ALT elevations
associated with increased glecaprevir
exposure.
Sofosbuvir/velpatasvir/ Serum concentrations of It is not recommended to
voxilaprevir sofosbuvir, velpatasvir and coadminister Kaletra and
voxilaprevir may be increased due sofosbuvir/velpatasvir/ voxilaprevir.
to P-glycoprotein, BCRP and
OATP1B1/3 inhibition by
lopinavir/ritonavir. However, only
the increase in voxilaprevir
exposure is considered clinically
relevant.
HCV protease inhibitors
Simeprevir 200 mg Simeprevir: It is not recommended to
daily (ritonavir 100 mg AUC: ↑ 7.2-fold co-administer Kaletra and simeprevir.
BID) Cmax: ↑ 4.7-fold
Cmin: ↑ 14.4-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) protease (HOS-085623) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage a7ffd699710dfcc905a1f28162df38c655a626dd6695d2536a15fef3b5c330fb · Zeichen 50777–52256 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94
HOS-109099 · Präparat HOS-093083
Lopinavir: ↔
Glecaprevir/pibrentasvir Serum concentrations may be Concomitant administration of
increased due to P-glycoprotein, glecaprevir/pibrentasvir and Kaletra
BCRP and OATP1B inhibition by is not recommended due to an
lopinavir/ritonavir. increased risk of ALT elevations
associated with increased
glecaprevir exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pibrentasvir (HOS-086298) glecaprevir (HOS-086297)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage d076cd4a85d70816f2529910c8ad5e9000a1fb04b5df3d1ad7bf4ac06098ba8c · Zeichen 51984–52557 im Abschnitt
Gegenanzeigen · Evra
EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch · Abschnitt 4.3 · PDF-Seite 5–6
HOS-110299 · Präparat HOS-093363
5
• Presence or risk of arterial thromboembolism (ATE)
• Arterial thromboembolism – current arterial thromboembolism, history of arterial
thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina
pectoris);
• Cerebrovascular disease – current stroke, history of stroke or prodromal condition
(e.g. transient ischaemic attack, TIA);
• Known hereditary or acquired predisposition for arterial thromboembolism, such as
hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies,
lupus anticoagulant);
• History of migraine with focal neurological symptoms;
• A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or
to the presence of one serious risk factor such as:
- diabetes mellitus with vascular symptoms
- severe hypertension
- severe dyslipoproteinaemia
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1
• Known or suspected carcinoma of the breast
• Carcinoma of the endometrium or other known or suspected oestrogen-dependent neoplasia
• Abnormal liver function related to acute or chronic hepatocellular disease
• Hepatic adenomas or carcinomas
• Undiagnosed abnormal genital bleeding
• Concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and
dasabuvir, medicinal products containing glecaprevir/pibrentasvir or
sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) dasabuvir (HOS-110302) voxilaprevir (HOS-108930) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-22T17:22:00Z · SHA-256 08ee5b4a9562d12725bc2847cb5a881102ab4ddbaaf7c1a2e28b65b78fd2ab5d · Passage 0b84b4ce379340aec479b3699d0b67d6f02d4b453bb9a5e3d40b02692d6515fc · Zeichen 895–2550 im Abschnitt
Wechselwirkungen · Evra
EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch · Abschnitt 4.5 · PDF-Seite 11
HOS-110304 · Präparat HOS-093363
Pharmacodynamic interactions
During clinical trials with patients treated for hepatitis C virus infections (HCV) with medicinal
products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin,
transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred
significantly more frequently in women using ethinyl estradiol-containing medications such as
combined hormonal contraceptives (CHCs). Additionally, also in patients treated with
glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir, ALT elevations were observed in
women using ethinyl estradiol-containing medications such as CHCs (see section 4.3).
Therefore, EVRA-users must switch to an alternative method of contraception (e.g., progestagen-only
contraception or non-hormonal methods) prior to starting therapy with these combination drug
regimens. EVRA can be restarted 2 weeks following completion of treatment with these combination
drug regimens.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) ribavirin (HOS-088127) dasabuvir (HOS-110302) voxilaprevir (HOS-108930) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-22T17:22:00Z · SHA-256 08ee5b4a9562d12725bc2847cb5a881102ab4ddbaaf7c1a2e28b65b78fd2ab5d · Passage a2c9d2476ababdf6aa70cd37d7f709e3b0de8b4455edc5193e41c8ca51311e4e · Zeichen 125–1104 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-112048 · Präparat HOS-093615
Co-administration with glecaprevir/pibrentasvir fixed-dose combination (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pibrentasvir (HOS-086298) glecaprevir (HOS-086297)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 4de4298cfb1133a5652b6d14106f842f438a3749b3771155bb4c5a4772d95fc2 · Zeichen 1560–1649 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.3 · PDF-Seite 40
HOS-112155 · Präparat HOS-093615
Co-administration with glecaprevir/pibrentasvir fixed-dose combination (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pibrentasvir (HOS-086298) glecaprevir (HOS-086297)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 4de4298cfb1133a5652b6d14106f842f438a3749b3771155bb4c5a4772d95fc2 · Zeichen 1418–1507 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8–9
HOS-112051 · Präparat HOS-093615
8
Co-administration of REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir
fixed-dose combination is contraindicated because of the increase in grazoprevir and elbasvir plasma
concentrations and potential for the increase in risk of ALT elevations associated with increased
grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in
the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma
concentrations (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) grazoprevir (HOS-108815)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage f08791b66cbe39a54ebdafa8a6dc0059e91e83d60f2f71fe12120c13410ef83c · Zeichen 814–1433 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-112063 · Präparat HOS-093615
The mechanism of interaction between
REYATAZ/ritonavir and
sofosbuvir/velpatasvir/voxilaprevir is
inhibition of OATP1B, P-gp, and CYP3A.
Glecaprevir Glecaprevir AUC: ↑553% (↑424% ↑714%) Co-administration of REYATAZ
300 mg/pibrentasvir 120 mg Glecaprevir Cmax: ↑306% (↑215% ↑423%) with glecaprevir/pibrentasvir is
once daily Glecaprevir Cmin: ↑1 330% (↑885% contraindicated because of the
(atazanavir 300 mg/ritonavir ↑1 970%) potential increase in the risk of
100 mg once daily*) ALT elevations due to a significant
Pibrentasvir AUC: ↑64% (↑48% ↑82%) increase in glecaprevir and
Pibrentasvir Cmax: ↑29% (↑15% ↑45%) pibrentasvir plasma concentrations
Pibrentasvir Cmin: ↑129% (↑95% ↑168%) (see section 4.3)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 00f49e5c0714dc97eb1ca47d912808f0ce2eee4f0239eaed7cee847a7cf8abcd · Zeichen 5864–6980 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-112064 · Präparat HOS-093615
*Effect of atazanavir and ritonavir on the
first dose of glecaprevir and pibrentasvir is
reported.
ANTIPLATELETS
Ticagrelor The mechanism of the interaction is Co-administration of REYATAZ
CYP3A4 inhibition by atazanavir and/or with ticagrelor is not recommended
ritonavir. due to potential increase in the
antiplatelet activity of ticagrelor.
Clopidogrel The mechanism of the interaction is Co-administration with clopidogrel
CYP3A4 inhibition by atazanavir and is not recommended due to
or/ritonavir. potential reduction of the
antiplatelet activity of clopidogrel.
Prasugrel The mechanism of the interaction is No dose adjustment is needed when
CYP3A4 inhibition by atazanavir and prasugrel is co-administered with
or/ritonavir. REYATAZ (with or without
ritonavir).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) clopidogrel (HOS-087927) prasugrel (HOS-112066) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage fd521896b4446bbb2c2aac91bcc7d85d91bd9ff839031dc48ca38ee0153ced32 · Zeichen 7014–8515 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 44
HOS-112157 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ
with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a
narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil, triazolam, orally administered midazolam, lomitapide, and ergot
alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). Co-administration of
REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed-dose
combination is contraindicated because of the increase in grazoprevir and elbasvir plasma
concentrations and potential for the increase in risk of ALT elevations associated with increased
grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in
the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma
concentrations (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) cisapride (HOS-085610) pibrentasvir (HOS-086298) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) glecaprevir (HOS-086297) grazoprevir (HOS-108815) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) terfenadine (HOS-085607) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8c472f02d161fbf877b321685a02acd6721db094612098433562a9a244834b35 · Zeichen 315–1385 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 45
HOS-112167 · Präparat HOS-093615
The mechanism of interaction between
REYATAZ/ritonavir and
sofosbuvir/velpatasvir/voxilaprevir is
inhibition of OATP1B, P-gp, and CYP3A.
Glecaprevir Glecaprevir AUC: ↑553% (↑424% ↑714%) Co-administration of
300 mg/pibrentasvir 120 mg Glecaprevir Cmax: ↑306% (↑215% ↑423%) REYATAZ with
once daily Glecaprevir Cmin: ↑1 330% (↑885% glecaprevir/pibrentasvir is
(atazanavir 300 mg/ritonavir ↑1 970%) contraindicated because of the
100 mg once daily*) potential increase in the risk of
Pibrentasvir AUC: ↑64% (↑48% ↑82%) ALT elevations due to a
Pibrentasvir Cmax: ↑29% (↑15% ↑45%) significant increase in
Pibrentasvir Cmin: ↑129% (↑95% ↑168%) glecaprevir and pibrentasvir
plasma concentrations
*Effect of atazanavir and ritonavir on the (see section 4.3)
first dose of glecaprevir and pibrentasvir is
reported.
ANTIPLATELETS
Ticagrelor The mechanism of the interaction is Co-administration of
CYP3A4 inhibition by atazanavir and/or REYATAZ with ticagrelor is
ritonavir. not recommended due to
potential increase in the
antiplatelet activity of
ticagrelor.
Clopidogrel The mechanism of the interaction is Co-administration with
CYP3A4 inhibition by atazanavir and clopidogrel is not
or/ritonavir. recommended due to potential
reduction of the antiplatelet
activity of clopidogrel.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) clopidogrel (HOS-087927) velpatasvir (HOS-108929) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage edfcf541a931e4b83eae4873165bcf47e213e3efb25690eb982fd8615b53d1c1 · Zeichen 5708–8232 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 20–21
HOS-116410 · Präparat HOS-094447
20
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and boosted PREZISTA may increase with PREZISTA and low dose
plasma concentrations of bosentan. ritonavir, the patient’s tolerability
of bosentan should be monitored.
Bosentan is expected to decrease plasma
concentrations of darunavir and/or its Co-administration of PREZISTA
pharmacoenhancer. co-administered with cobicistat
(CYP3A induction) and bosentan is not recommended.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Boosted PREZISTA may increase the Concomitant use of boosted
exposure to grazoprevir. PREZISTA and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected Boosted PREZISTA must not be
(Hypericum perforatum) to decrease the plasma concentrations of used concomitantly with products
darunavir or its pharmacoenhancers. containing St John’s Wort
(CYP450 induction) (Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with boosted rhabdomyolysis. Concomitant use
PREZISTA. of boosted PREZISTA with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and boosted
atorvastatin Cmax ↑ ≈2 fold PREZISTA is desired, it is
#
darunavir/ritonavir recommended to start with an
atorvastatin dose of 10 mg once
atorvastatin AUC ↑ 290% Ω daily. A gradual dose increase of
atorvastatin may be tailored to the
atorvastatin Cmax ↑ 319% Ω
clinical response.
atorvastatin Cmin ND Ω
Ω
with darunavir/cobicistat 800/150 mg
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and boosted PREZISTA is
pravastatin Cmax ↑ 63% required, it is recommended to
¶
an up to five-fold increase was seen in a start with the lowest possible dose
limited subset of subjects of pravastatin and titrate up to the
desired clinical effect while
monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) cobicistat (HOS-088111) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6c740a1d89386aee87cf1f30365ea4ce6beb0a0dc719c309b037ce4e6094f9e7 · Zeichen 57628–63489 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62–63
HOS-116528 · Präparat HOS-094447
62
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and PREZISTA co-administered with with PREZISTA and low dose
low dose ritonavir may increase plasma ritonavir, the patient’s tolerability
concentrations of bosentan. of bosentan should be monitored.
Bosentan is expected to decrease plasma
concentrations of darunavir and/or its
pharmacoenhancer.
(CYP3A induction)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir PREZISTA with low dose ritonavir may Concomitant use of PREZISTA
increase the exposure to grazoprevir. with low dose ritonavir and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected PREZISTA co-administered with
(Hypericum perforatum) to decrease the plasma concentrations of low dose ritonavir must not be
darunavir and ritonavir. used concomitantly with products
(CYP450 induction) containing St John’s Wort
(Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with rhabdomyolysis. Concomitant use
PREZISTAco-administered with low of PREZISTA co-administered
dose ritonavir. with low dose ritonavir with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and PREZISTA
atorvastatin Cmax ↑ ≈2 fold co-administered with low dose
#
darunavir/ritonavir ritonavir is desired, it is
recommended to start with an
atorvastatin dose of 10 mg once
daily. A gradual dose increase of
atorvastatin may be tailored to the
clinical response.
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and PREZISTA co-administered
pravastatin Cmax ↑ 63% with low dose ritonavir is required,
¶
an up to five-fold increase was seen in a it is recommended to start with the
limited subset of subjects lowest possible dose of pravastatin
and titrate up to the desired clinical
effect while monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f0e95b466409a0cf2f8a9197f2461639fabe461c2c18b467893f52ceb3fe5916 · Zeichen 48435–54296 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 102–103
HOS-116618 · Präparat HOS-094447
102
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and boosted PREZISTA may increase with PREZISTA and low dose
plasma concentrations of bosentan. ritonavir, the patient’s tolerability
Bosentan is expected to decrease plasma of bosentan should be monitored.
concentrations of darunavir and/or its
pharmacoenhancer. Co-administration of PREZISTA
(CYP3A induction) co-administered with cobicistat
and bosentan is not recommended.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Boosted PREZISTA may increase the Concomitant use of boosted
exposure to grazoprevir. PREZISTA and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected Boosted PREZISTA must not be
(Hypericum perforatum) to decrease the plasma concentrations of used concomitantly with products
darunavir or its pharmacoenhancers. containing St John’s Wort
(CYP450 induction) (Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with boosted rhabdomyolysis. Concomitant use
PREZISTA. of boosted PREZISTA with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and boosted
atorvastatin Cmax ↑ ≈2 fold PREZISTA is desired, it is
#
darunavir/ritonavir recommended to start with an
atorvastatin dose of 10 mg once
atorvastatin AUC ↑ 290% Ω daily. A gradual dose increase of
atorvastatin Cmax ↑ 319% Ω atorvastatin may be tailored to the
clinical response.
atorvastatin Cmin ND Ω
Ω
with darunavir/cobicistat 800/150 mg
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and boosted PREZISTA is
pravastatin Cmax ↑ 63% required, it is recommended to
¶
an up to five-fold increase was seen in a start with the lowest possible dose
limited subset of subjects of pravastatin and titrate up to the
desired clinical effect while
monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) cobicistat (HOS-088111) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage bf054a2c5f8c6d1a5be5b88714b31789a51a1dde2eabf2bbfe2ccb65fdbce96b · Zeichen 57100–62897 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.